Skip to main content
Zentek Ltd. logo

Zentek Ltd. — Investor Relations & Filings

Ticker · ZTEK TSXV Professional, scientific and technical activities
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-05-09 Regulatory Filings
Country CA Canada
Listing TSXV ZTEK

About Zentek Ltd.

https://www.zentek.com/

Zentek Ltd. is an intellectual property development and commercialization company focused on applying advanced nanotechnology and nanomaterials, specifically graphene, to solve complex challenges in health, safety, and the environment. The company specializes in developing and commercializing next-generation healthcare solutions across prevention, detection, and treatment. Zentek utilizes strategic partnerships to advance its patented nanotechnologies. A key commercialized product is ZenGUARD™, an antimicrobial coating that employs a graphene-silver combination to significantly enhance viral and bacterial filtration performance in applications such as surgical masks and air filters.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2024-05-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a case study by Zentek Ltd. on HVAC filter cost savings and environmental benefits for the City of Toronto. It contains no financial statements, regulatory filings, or detailed financial data. It is not an earnings release, annual or interim report, or any form of regulatory filing. The content focuses on operational and environmental benefits rather than financial results or governance. It is a corporate announcement about a study completion, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-05-07 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing positive results in the development of a therapeutic and prophylactic for avian influenza (H5N1) by Zentek and its subsidiary Triera Biosciences. It discusses scientific progress, patent filing, and future testing plans. There are no financial statements, regulatory filings, voting results, or management changes. The content is focused on a scientific and product development update rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The document is best classified as a general corporate announcement about research and development progress, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2024-05-06 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing changes in the company's board and management, specifically resignations and appointments of key personnel. It includes details about stock options granted to a newly appointed advisory board member. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses solely on management changes and related corporate governance matters. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 4726 characters, which is sufficient to contain substantive information about management changes rather than a brief announcement or a report publication notice.
2024-05-03 English
News release - English.pdf
Regulatory Filings
2024-04-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new U.S. distribution agreement between Zentek Ltd. and Medwell Solutions for ZenGUARD™-Enhanced Surgical Masks. It discusses the terms of the agreement, company backgrounds, and forward-looking statements. There is no financial data, no regulatory filing references, no mention of shareholder votes, no management or board changes, no earnings or interim report data, and no audit or legal proceedings information. The document is a corporate announcement about a business partnership and distribution agreement, which fits best under Capital/Financing Update (CAP) as it relates to commercial and strategic business development activities. The document length is about 5944 characters, which is sufficient for a full announcement rather than a brief note. Therefore, the classification is CAP with high confidence.
2024-04-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.